Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth
Medicine pill is seen with Merck logo and words ‘Molnupiravir’ and ‘COVID-19’ displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. Jakub Porzycki | NurPhoto | Getty Images Merck sold $3.2 billion of its oral antiviral treatment for Covid in the first quarter, fueling the company’s strong revenue growth. Merck on Thursday soundly beat Wall Street profit and revenue forecasts, reporting earnings of $2.14 per share on $15.9 billion in revenue. The company raised its 2022 earnings guidance to between $7.24 and $7.36 per share on $56.9 billion to $58.1 billion in revenue. It previously projected earnings per share between $7.12 to $7.27 on revenue of between $56.1 billion to $57.6Continue Reading